These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1969878)

  • 1. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD.
    Sprent J; Schaefer M; Korngold R
    J Immunol; 1990 Apr; 144(8):2946-54. PubMed ID: 1969878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
    Moser M; Sharrow SO; Shearer GM
    J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences.
    Korngold R; Sprent J
    J Immunol; 1985 Nov; 135(5):3004-10. PubMed ID: 3876371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts.
    Sprent J; Schaefer M; Gao EK; Korngold R
    J Exp Med; 1988 Feb; 167(2):556-69. PubMed ID: 2964497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Split tolerance in spleen chimeras.
    Sprent J; Hurd M; Schaefer M; Heath W
    J Immunol; 1995 Feb; 154(3):1198-206. PubMed ID: 7822792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones.
    Parkman R
    J Immunol; 1986 May; 136(10):3543-8. PubMed ID: 2871104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
    Thiele DL; Charley MR; Calomeni JA; Lipsky PE
    J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens.
    Hamilton BL
    J Immunol; 1987 Oct; 139(8):2511-5. PubMed ID: 3498761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
    Korngold R
    Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
    Leibnitz RR; Lipsky PE; Thiele DL
    J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
    Korngold R; Wettstein PJ
    J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency in L3T4+ but not in Lyt-2+ T helper cell function.
    Moser M; Mizuochi T; Sharrow SO; Singer A; Shearer GM
    J Immunol; 1987 Mar; 138(5):1355-62. PubMed ID: 2949013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GVHR elicited by products of class I or class II loci of the MHC: analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy.
    Piguet PF
    J Immunol; 1985 Sep; 135(3):1637-43. PubMed ID: 2410497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
    Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
    Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.